Abrahamson Cyrus W, Landini Abbey L, Kuriakose Jonathan P, Stewart Jasmine, Burns James A, Stein Andrew P
Northwestern University Feinberg School of Medicine Chicago Illinois USA.
Department of Otolaryngology-Head and Neck Surgery Northwestern University Chicago Illinois USA.
OTO Open. 2025 Sep 5;9(3):e70153. doi: 10.1002/oto2.70153. eCollection 2025 Jul-Sep.
Nebulized ciprofloxacin-dexamethasone represents an adjuvant medication utilized following airway surgery. However, minimal objective information exists on this treatment, especially over more extended periods. This study measured the safety, tolerability, and adherence to nebulized ciprofloxacin-dexamethasone utilized in the outpatient setting after endoscopic airway surgery for adult patients.
Retrospective cohort study.
Single-institution academic center.
All patients with laryngotracheal stenosis managed by a single surgeon from 2021 to 2024 who underwent endoscopic airway surgery were included. Patient demographics, stenosis etiology, comorbidities, and ciprofloxacin-dexamethasone prescriptions were documented. Ciprofloxacin-dexamethasone dose, duration of treatment, adherence, tolerability, and side effects were collected. Potential side effects evaluated included allergic reactions, postoperative infections and pneumonia, and Cushingoid symptoms.
Sixty-nine adult patients underwent endoscopic airway surgery to treat laryngotracheal stenosis, and fifty-nine were prescribed nebulized ciprofloxacin-dexamethasone postoperatively. Fifty-two patients (88.1%) filled their prescription and utilized this treatment regimen. Importantly, over 90% (47/52) of this cohort completed the prescribed four-week regimen. Four patients (7.7%) experienced temporary side effects, which dissipated after discontinuation: two altered taste/smell, one nausea/chills, and one blurry vision. No significant complications were reported.
Nebulized ciprofloxacin-dexamethasone is a safe and tolerable treatment for adult patients after endoscopic airway surgery. The majority of patients were able to obtain, adhere to, and successfully utilize this medication in the outpatient setting. This study represents an important step in understanding the tolerability of this adjuvant treatment regimen.
雾化吸入环丙沙星-地塞米松是气道手术后使用的一种辅助药物。然而，关于这种治疗的客观信息极少，尤其是在更长时间内。本研究测量了成年患者在内镜气道手术后门诊使用雾化吸入环丙沙星-地塞米松的安全性、耐受性和依从性。
回顾性队列研究。
单一机构学术中心。
纳入2021年至2024年由同一外科医生治疗的所有接受内镜气道手术的喉气管狭窄患者。记录患者的人口统计学资料、狭窄病因、合并症以及环丙沙星-地塞米松处方。收集环丙沙星-地塞米松剂量、治疗持续时间、依从性、耐受性和副作用。评估的潜在副作用包括过敏反应、术后感染和肺炎以及库欣样症状。
69例成年患者接受了内镜气道手术以治疗喉气管狭窄，其中59例术后被处方雾化吸入环丙沙星-地塞米松。52例患者（88.1%）取药并采用了该治疗方案。重要的是，该队列中超过90%（47/52）的患者完成了规定的四周疗程。4例患者（7.7%）出现了暂时的副作用，停药后消失：2例味觉/嗅觉改变，1例恶心/寒战，1例视力模糊。未报告重大并发症。
雾化吸入环丙沙星-地塞米松对于成年患者内镜气道手术后是一种安全且耐受性良好的治疗方法。大多数患者能够在门诊获得、坚持并成功使用这种药物。本研究是了解这种辅助治疗方案耐受性的重要一步。
